Benoit Barteau
Direttore/Membro del Consiglio presso Igyxos SA
Provenienza dei contatti di primo grado di Benoit Barteau
Entità | Tipo di entità | Settore Industriale | |
---|---|---|---|
Alentis Therapeutics AG
Alentis Therapeutics AG Pharmaceuticals: MajorHealth Technology Alentis Therapeutics AG develops novel medications to treat advanced liver diseases and cancers. The company was founded by Neil Goldsmith on March 1, 2019 and is headquartered in Basel, Switzerland.
8
| Holding Company | Pharmaceuticals: Major | 8 |
Tridek-One Therapeutics SAS
Tridek-One Therapeutics SAS Miscellaneous Commercial ServicesCommercial Services Tridek-One Therapeutics SAS is a French private biotechnology company founded in 2018. The company is based in Paris, France. Tridek-One's scientific founders at INSERM conducted groundbreaking research on the role of CD31 in the modulation of the immune response, which forms the basis of the company's work. The company was founded in 2019 by Giuseppina Caligiuri, Antonino Nicoletti, and the CEO is Laurence de Schoulepnikoff.
6
| Holding Company | Miscellaneous Commercial Services | 6 |
Igyxos SA
Igyxos SA Pharmaceuticals: MajorHealth Technology Igyxos SA engages in the development of an innovative medical and pharmaceutical technologies in the field of human fertility. It is involved in all phases of development, from the discovery of promising targets to the identification of potential lead compounds. The company was founded by Marie-Christine Maurel and is headquartered in Nouzilly, France.
3
| Holding Company | Pharmaceuticals: Major | 3 |
Grafico delle società connesse in secondo grado
Relazione in diverse aziende
Società connesse a Benoit Barteau tramite i suoi contatti personali
Società | Settore | Persone collegate | Posizione principale |
---|---|---|---|
ROCHE HOLDING AG | Pharmaceuticals: Major | Corporate Officer/Principal | |
Foley & Lardner LLP
Foley & Lardner LLP Miscellaneous Commercial ServicesCommercial Services Foley & Lardner LLP engages in the provision of legal services. Its practice areas include employee benefits and executive compensation, environmental, estates and trusts, finance, international tax and transfer pricing, private equity and venture capital, real estate, securities, commodities and exchange regulation, taxation, and transactions. The company was founded by Asahel Finch and William Pitt Lynde on September 8, 1842 and is headquartered in Milwaukee, WI. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
Advent Venture Partners LLP
Advent Venture Partners LLP Investment ManagersFinance Advent Venture Partners LLP (AVP) is a private equity/venture capital firm founded in 1981 by David James Scott Cooksey. The firm is headquartered in London, United Kingdom. | Investment Managers | Private Equity Investor Corporate Officer/Principal | |
Phase4 Partners Ltd.
Phase4 Partners Ltd. Investment ManagersFinance Phase4 Ventures ltd (Phase4 Ventures) is a venture capital subsidiary of Nomura International Plc founded in 1999. The firm is headquartered in London, UK. | Investment Managers | Investment Committee Member | |
FLEXION THERAPEUTICS, INC. | Pharmaceuticals: Major | Director/Board Member Director of Finance/CFO | |
2020, Inc.
2020, Inc. Medical/Nursing ServicesHealth Services 2020, Inc. offers eye care services. It also offers delivers on-site eye care and eye exams to businesses and their employees via a mobile eye clinic. The company was founded by Howard Bornstein in 2013 and is headquartered in Boston, MA. | Medical/Nursing Services | Director/Board Member | |
Pinteon Therapeutics, Inc.
Pinteon Therapeutics, Inc. BiotechnologyHealth Technology Pinteon Therapeutics, Inc. develops cancer and CNS therapeutics. It focuses on the discovery and development of therapeutics targeting Pin1. The firm specializes in aberrant disease processes and improves patient outcomes in medical need indications. The company is headquartered in Newton Centre, MA. | Biotechnology | Director/Board Member | |
Cancer Targeting Systems, Inc.
Cancer Targeting Systems, Inc. BiotechnologyHealth Technology Cancer Targeting Systems, Inc. offers cancer care. The firm focuses on delivering cancer theranostic products combining imaging with therapy. The company was founded by Martin Pomper and Will West and is headquartered in Boston, MA. | Biotechnology | Director/Board Member | |
Iowa State University | College/University | Doctorate Degree | |
University of Strathclyde | College/University | Undergraduate Degree | |
University of Utrecht | College/University | Graduate Degree | |
AM-Pharma Holding BV
AM-Pharma Holding BV Pharmaceuticals: MajorHealth Technology AM-Pharma Holding BV operates as a financial holding company with interests in the bio-medical sector. The company was founded by Rudd Brands and is headquartered in Bunnik, Netherlands. | Pharmaceuticals: Major | Director/Board Member Chief Executive Officer | |
Morningside Group Ltd.
Morningside Group Ltd. Investment ManagersFinance Morningside Group (Morningside Group) is a venture capital and private equity firm founded in 1986 by Lok Chung Chan and Chi Chung Chan. The firm is headquartered in Hong Kong. | Investment Managers | Consultant / Advisor | |
CellCentric Ltd.
CellCentric Ltd. Pharmaceuticals: MajorHealth Technology CellCentric Ltd. develops and commercializes small molecule inhibitors for cancer. Its active programs include inhibitors to histone methyltransferases, histone demethylases and epigenetic enzymes that act via ubiquitin. The company was founded by Alun Huw Jones, Catherine Denise Prescott, Azim Surani and William Henry Lewarne West in May 2004 and is headquartered in Cambridge, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member | |
University of Turin | College/University | Doctorate Degree | |
AM-Pharma BV
AM-Pharma BV BiotechnologyHealth Technology AM-Pharma BV operates as a biopharmaceutical company. It engages in the development of proprietary recombinant human Alkaline Phosphatase. The firm’s products include Acute Kidney Injury, Inflammatory Bowel Diseases and Hypophosphatasia. The company was founded in 2001 and is headquartered in Bunnik, the Netherlands. | Biotechnology | Director/Board Member Director/Board Member | |
Bellevue Asset Management (Venture Capital)
Bellevue Asset Management (Venture Capital) Investment ManagersFinance Bellevue Asset Management (Venture Capital) is the venture capital arm of Bellevue Asset Management AG, a subsidiary of Bellevue Group AG (SW: BBN) headquartered in Zurich, Switzerland. The firm was founded in 1993. | Investment Managers | Private Equity Investor Private Equity Investor | |
Manchester Business School | College/University | Masters Business Admin | |
GreenLight Biosciences, Inc.
GreenLight Biosciences, Inc. BiotechnologyHealth Technology GreenLight Biosciences, Inc. engages in a biotechnology company.. It delivers attractive solution for production of chemicals and fuels from renewable resources, eliminating the need for petroleum feedstocks. The company was founded by Andrey J. Zarur, Marta Ortega-Valle, and James R. Swartz and is headquartered in Medford, MA. | Biotechnology | Director/Board Member | |
HeatMatrix Group BV
HeatMatrix Group BV Building ProductsProducer Manufacturing HeatMatrix Group BV develops and manufactures plastic heat exchangers for waste heat recovery from industrial corrosive flue gas. The firm’s heat exchangers can be used in the petrochemicals and chemicals, bio-energy, food, agricultural, and paper industries. Its products include air pre-heater, hybrid exchanger, gas to liquid, and in situ cleaning system. The company was founded by Erik van den Berg in 2008 and is headquartered in Geldermalsen, the Netherlands. | Building Products | Founder | |
Amal Therapeutics SA
Amal Therapeutics SA BiotechnologyHealth Technology Amal Therapeutics SA engages in the development of peptide-based therapeutic cancer vaccines. It offers KISMA, a novel peptide/protein-based immunization technology platform, which is self-adjuvanting and enables the assembly within one chimeric fusion protein of elements essential to generate potent immunity. The company was founded by Madiha Derouazi on September 3, 2012 and is headquartered in Geneva, Switzerland. | Biotechnology | Director/Board Member Chief Operating Officer | |
Inotrem SA
Inotrem SA BiotechnologyHealth Technology Inotrem SA specializes in the development of therapeutic approaches based on its proprietary TREM-1 platform. The firm focuses on the control of immune reactions in acute inflammatory diseases. The company was founded by Jean-Jacques Garaud, Marc Derive and Sebastien Gibot in 2013 and is headquartered in Paris, France. | Biotechnology | Director/Board Member | |
The University of Iowa College of Law | College/University | Graduate Degree | |
ESCP Europe Campus London | College/University | Undergraduate Degree | |
Memo Therapeutics AG
Memo Therapeutics AG BiotechnologyHealth Technology Memo Therapeutics AG develops recombinant immunoglobulins and human-derived monoclonal antibodies. Its products include human antibodies, human immune repertoire analysis, classic antibody discovery and pipeline. The company was founded by Christoph Esslinger on November 29, 2012 and is headquartered in Basel, Switzerland. | Biotechnology | Chief Executive Officer | |
KEZAR LIFE SCIENCES, INC. | Biotechnology | Director/Board Member | |
Therachon SAS
Therachon SAS BiotechnologyHealth Technology TherAchon SAS provides biotechnology services. It specializes in research and development for achondroplasia and its associated complications. The company was founded by Elvire Gouze in 2014 and is headquartered in Biot, France. | Biotechnology | Chief Executive Officer | |
ENYO Pharma SA
ENYO Pharma SA BiotechnologyHealth Technology ENYO Pharma SA operates as a biopharmaceutical company. The firm's research and development is focused on human infecting viruses, with the first two programs being dedicated to the treatment of severe and seasonal flu and chronic hepatitis B. The company was founded by Jacky Vonderscher, Jean-Jacques Garaud, Benoît de Chassey, Laurène Meyniel-Schicklin, Patrice André and Vincent Lotteau January 2014 and is headquartered in Lyon, France. | Biotechnology | Director/Board Member Director/Board Member | |
Step Pharma SAS
Step Pharma SAS Pharmaceuticals: MajorHealth Technology Step Pharma SAS develops drugs for immunosuppressive therapies. The company was founded by Geoffroy de Ribains, Alain Fischer, and Sylvain Latour and is headquartered in Paris, France. | Pharmaceuticals: Major | Chairman | |
Alms Therapeutics SAS
Alms Therapeutics SAS Miscellaneous Commercial ServicesCommercial Services Alms Therapeutics SAS provides research and development in the treatment of diabetes. The company was founded by Jason Robert Dinges on July 4, 2017 and is headquartered in Paris, France. | Miscellaneous Commercial Services | Founder | |
Pureos Partners AG
Pureos Partners AG Investment ManagersFinance Pureos Partners AG (Pureos Partners) is a venture capital division of Bellevue Asset Management AG founded in 2017. The firm is headquartered in Zurich, Switzerland. | Investment Managers | Private Equity Investor Private Equity Investor Private Equity Investor | |
LAVA THERAPEUTICS N.V. | Biotechnology | Founder | |
Apic Bio, Inc.
Apic Bio, Inc. Packaged SoftwareTechnology Services Apic Bio, Inc. engages in the development of treatment for neurological and liver diseases. It offers THRIVE, a platform that silences a mutant gene product and replaces a normal gene product in a single dual function vector. The company was founded by Robert H. Brown, Jr., John Reilly, and Christian Mueller in 2017 and is headquartered in North Cambridge, MA. | Packaged Software | Director/Board Member | |
Alliance Manchester Business School | College/University | Masters Business Admin | |
The School of Pharmacy University of London | College/University | Doctorate Degree | |
Pheno Therapeutics Ltd.
Pheno Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Pheno Therapeutics Ltd. operates as a biotechnology company. The firm develops remyelinating therapies for the unmet need for a neuroprotective therapy for multiple sclerosis. The company was founded on October 31, 2018 and is headquartered in Edinburgh, the United Kingdom. | Miscellaneous Commercial Services | Chief Executive Officer | |
Prilenia Therapeutics BV
Prilenia Therapeutics BV BiotechnologyHealth Technology Prilenia Therapeutics BV develops and manufactures pharmaceuticals. The company was founded in 2018 and is headquartered in Naarden, the Netherlands. | Biotechnology | Director/Board Member | |
VectivBio AG
VectivBio AG BiotechnologyHealth Technology VectivBio AG is a clinical-stage biotechnology company. The firm focuses on developing transformational therapeutics for patients living with serious and rare diseases. Its program apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). The company was founded by Luca Santarelli in 2019 and is headquartered in Basel, Switzerland. | Biotechnology | Director/Board Member Founder | |
Pandeia Therapeutics Ltd. | Founder | ||
NewAmsterdam Pharma Holding BV
NewAmsterdam Pharma Holding BV BiotechnologyHealth Technology Part of NewAmsterdam Pharma Co. NV, NewAmsterdam Pharma Holding BV is a Dutch company that engages in research and development of transformative therapies for cardio metabolic diseases. The company is based in Naarden, the Netherlands. The company was founded in 2019 by John Jacob Pieter Kastelein. Michael H. Davidson has been the CEO of the company since 2020. NewAmsterdam Pharma Holding was acquired by Frazier Lifesciences Acquisition Corp. on November 22, 2022 for $468.74 million. | Biotechnology | Director/Board Member | |
Cimeio Therapeutics AG
Cimeio Therapeutics AG Packaged SoftwareTechnology Services Cimeio Therapeutics AG is an applied gene editing and immunotherapy company based in Basel, Switzerland. Cimeio is developing a portfolio of shielded-cell & immunotherapy pairs™ (scip) that have the potential to transform hematopoietic stem cell transplant. The Swiss company's technology platform is based on the design and expression of modified variants of naturally occurring cell surface proteins in hscs. These novel variants maintain their function but are resistant to depletion when targeted by a paired immunotherapy which has high affinity for the wild-type version of these proteins. Cimeio is the leader of the field of epitope editing and is developing a portfolio of shielded-cell & immunotherapy pairs™ (scip), novel immunotherapies which have the potential to transform treatment of hematologic diseases. The company develops state-of-the-art immunotherapies, along with paired, modified variants of naturally occurring cell surface proteins in hscs. These immunotherapies have significant therapeutic potential, which Cimeio is using to develop curative treatments for patients with hematologic malignancies, autoimmune disorders, and genetic diseases. The company was founded by Lukas Jeker and the CEO is Thomas Fuchs. | Packaged Software | Director/Board Member | |
Lead Pharma Holding BV
Lead Pharma Holding BV Pharmaceuticals: MajorHealth Technology Lead Pharma Holding BV develops small-molecule drugs for the treatment of autoimmune diseases and cancer. It specializes in medicinal, computational, and protein chemistry, x-ray crystallography, cell biology, and integration x-omics. The company was founded by Ad van Gorp, Leon de Windt, and Pieter Doevendans in 2007 and is headquartered in Oss , the Netherlands. | Pharmaceuticals: Major | Director/Board Member | |
NewAmsterdam Pharma BV
NewAmsterdam Pharma BV Pharmaceuticals: MajorHealth Technology NewAmsterdam Pharma BV develops novel drugs to treat dyslipidemia. It operates as a biotechnology company and develops anti-dyslipidemic compounds in cardiovascular disease indications. The firm's product DEZ-001 develops a potent cholesteryl ester transfer protein inhibitor that has shown a decrease of low-density lipoprotein levels, and an increase of high-density lipoprotein levels. The company was founded by John J. P. Kastelein in 2012 and is headquartered in Naarden, the Netherlands. | Pharmaceuticals: Major | Director/Board Member |
Statistiche
Distribuzione geografica
Svizzera | 12 |
Stati Uniti | 12 |
Regno Unito | 11 |
Paesi Bassi | 10 |
Francia | 8 |
Settori
Health Technology | 27 |
Consumer Services | 11 |
Finance | 6 |
Commercial Services | 4 |
Technology Services | 3 |
Posizioni
Director/Board Member | 100 |
Founder | 20 |
Chief Executive Officer | 16 |
Corporate Officer/Principal | 15 |
Chairman | 14 |
Contatti più connessi
- Borsa valori
- Insiders
- Benoit Barteau
- Connessioni Società